Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00613405
Other study ID # HR#17195
Secondary ID R21DA022424R21DA
Status Completed
Phase N/A
First received February 11, 2008
Last updated April 23, 2013
Start date January 2008
Est. completion date May 2009

Study information

Verified date April 2013
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to explore the interaction between stress and marijuana cues, in hopes that it may lead to the development of new treatments for marijuana dependence.


Description:

Although use of marijuana is widespread, little research has focused on the treatment of marijuana use disorders or on predictors of relapse. Although several factors contributing to relapse have been explored in other dependencies (i.e., alcohol, cocaine), little research has focused on drug cue-related or stress-induced relapse in marijuana-dependent individuals. Cue reactivity is a construct measured in a laboratory procedure where an individual's subjective, behavioral, and physiological responses are assessed following exposure to drug-related environmental cues or stressors. Investigating the effects of drug-related environmental cues and stress in marijuana-dependent individuals will be useful in guiding treatment development.


Recruitment information / eligibility

Status Completed
Enrollment 87
Est. completion date May 2009
Est. primary completion date May 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Meets Diagnostic and Statistical Methods (DSM)-IV Criteria for Marijuana Dependence

- Between the ages of 18 and 65

- Must abstain from marijuana use the day of testing and other drug use three days prior to testing

Exclusion Criteria:

- Must not be taking any psychoactive medication, or medication that alters the hypothalamic pituitary adrenal (HPA) Axis functioning

- Must not be taking any medications that alter heart rate or skin conductance monitoring

- Cannot meet criteria for current major Axis I disorder (may alter response to stress)

- Cannot be morbidly obese (Body Mass Index >39)

- Cannot meet current abuse or dependence criteria of other substances in past 90 days

- Must not have a medical condition that impacts HPA functioning (Hypertension, chronic pain, Addison's disease)

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Other:
Stress + cue exposure
Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
No stress + cue exposure
Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).

Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (2)

Lead Sponsor Collaborator
Medical University of South Carolina National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subjective Craving of Marijuana Defined as the score on the Marijuana Craving Questionnaire (MCQ), range 7-84, higher scores indicate more craving approx 2.5 hours (before, during and after exposure to stressor condition as well as exposure to neutral and marijuana-associated cues). No
Secondary Physiological Assessments: Serum Cortisol, ACTH, BP, HR, and GSR ~ 2.5 hours (before, during and after exposure to stressor condition as well as exposure to neutral and marijuana-associated cues). No
Secondary Feelings of Stress/Anxiety as Measured by the State-Trait Inventory (STAI) ~2 hours No
Secondary Current Mood as Assessed by the Mood Form ~2 hours No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00673647 - CANDIS-II: Evaluation of the Cognitive-behavioral Treatment Programme CANDIS Phase 3